Associated tags: GIST, European, Cancer, Health, Pharmaceutical, Biotechnology, Oncology, Pharmaceutical industry, Clinical Trials, Research, Patient
Locations: NEW YORK, EUROPE, GERMANY, NY, LONDON, ILLINOIS, CHICAGO, IRELAND, ROMANIA, CZECH REPUBLIC, HUNGARY, CENTRAL, GREECE, POLAND, HAIR, VICTORIA, UNITED STATES, NORTH AMERICA, MASSACHUSETTS
Biotechnology,
Pharmaceutical,
Health,
Oncology,
USD,
Patient,
Cancer,
Acquisition,
Research,
Growth,
GIST,
Tenosynovial giant cell tumor,
ONO,
ULK,
TGCT,
Ono Pharmaceutical,
Disease,
BofA Securities,
Drug discovery,
Pharmaceutical industry Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world.
Key Points:
- Together, ONO and Deciphera will accelerate their shared vision to deliver innovative new drugs and serve patients around the world.
- If the tender offer conditions are not satisfied, ONO may be required to extend the tender offer under certain circumstances.
- Upon completion of the Acquisition, Deciphera will operate as a standalone business of ONO Group, from its headquarters in Waltham, Massachusetts.
- J.P. Morgan Securities LLC is serving as exclusive financial advisor to Deciphera and Goodwin Procter LLP is serving as legal counsel.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET.
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16, 2024 at 11:30 AM ET.
- A live webcast of the fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations .
- A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Retrieved on:
Tuesday, February 27, 2024
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences:
TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 1:30 PM ET in Boston, MA
Leerink Partners Global Biopharma Conference on Monday, March 11, 2024 at 2:40 PM ET in Miami Beach, FL
Barclays Global Healthcare Conference on Wednesday, March 13, 2024 at 8:00 AM ET in Miami Beach, FL
Live webcasts will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations .
- All webcast replays will be archived on the Company’s website for 90 days following the presentation.
Retrieved on:
Tuesday, February 6, 2024
Biotechnology,
Pharmaceutical,
Health,
Oncology,
OS,
KIT,
European,
Investigational New Drug,
Trial of the century,
DNA,
Research,
Patient,
IND,
Autophagy,
ASCO,
GIST,
Public expenditure,
FDA,
EMA,
MAA,
Part,
Food,
Society,
TGCT,
Gastrointestinal stromal tumor,
European Medicines Agency,
Sunitinib,
Neoplasm,
Cancer,
INSIGHT,
Tenosynovial giant cell tumor,
NDA,
Nature Medicine,
Pharmaceutical industry Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the fourth quarter and year ended December 31, 2023 and provided a corporate update.
- Expects to present updated results from the Phase 1/2 study of vimseltinib in TGCT in the second half of 2024.
- Expects to initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of chronic graft versus host disease (cGVHD) in the fourth quarter of 2024.
- Cost of Sales: Cost of sales were $1.8 million in the fourth quarter of 2023, which includes $0.9 million in cost of product sales, compared to cost of product sales of $0.7 million for the fourth quarter of 2022.
Retrieved on:
Thursday, February 1, 2024
Science,
Other Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
Webcast,
Cancer,
Conference Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 9:00 AM ET in New York, NY.
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that members of the management team will participate in a fireside chat at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference on Thursday, February 8, 2024 at 9:00 AM ET in New York, NY.
- A live webcast of the fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations .
- A replay of the webcast will be archived on the Company’s website for 90 days following the presentation.
Retrieved on:
Thursday, February 1, 2024
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024.
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 6, 2024.
- In connection with the earnings release, Deciphera’s management team will host a live conference call and webcast at 8:00 AM ET on Tuesday, February 6, 2024, to discuss the Company’s financial results and provide a corporate update.
- The conference call may be accessed via this link: https://register.vevent.com/register/BI7a0bbbeb53864df9a854d959bbbae709
A live webcast of the conference call will be available in the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations .
- A replay will be available on the Company’s website approximately two hours after the conference call and will be available for 30 days following the call.
Retrieved on:
Thursday, January 18, 2024
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
Health,
FDA,
Clinical Trials,
Patient,
Progression-free survival,
KIT,
Neoplasm,
OS,
Hypertension,
ASCO,
Fatigue,
Society,
Cancer,
Myalgia,
Survival rate,
Public health,
INSIGHT,
AP,
PFS,
Safety,
Diarrhea,
GIST,
Sunitinib,
Nature Medicine,
Preventive healthcare,
Pharmaceutical industry There were fewer patients with Grade 3/4 drug-related treatment emergent adverse events (TEAE) with QINLOCK (26.5%) compared with sunitinib (55.2%).
Key Points:
- There were fewer patients with Grade 3/4 drug-related treatment emergent adverse events (TEAE) with QINLOCK (26.5%) compared with sunitinib (55.2%).
- Dose interruptions and reductions as well as treatment discontinuations due to TEAEs were lower with QINLOCK versus sunitinib.
- Patients with mutations in KIT exon 11 and 17/18 had improved progression-free survival, objective response rate, and overall survival with QINLOCK versus sunitinib.
- Based on the results of this prespecified exploratory objective in INTRIGUE, the Company is enrolling the INSIGHT pivotal Phase 3 clinical study of QINLOCK in second-line GIST patients with mutations in KIT exon 11 and 17/18 only.
Research,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Oncology,
Gastrointestinal stromal tumor,
Food,
Neoplasm,
IND,
INSIGHT,
Autophagy,
FDA,
MAA,
Cetuximab,
European,
Encorafenib,
Public expenditure,
KIT,
NDA,
Cancer,
European Medicines Agency,
Part,
TGCT,
MEK,
Patient,
GIST,
Pharmaceutical industry Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2024 and planned 2024 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2023 revenue.
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today highlighted its strategic outlook for 2024 and planned 2024 corporate milestones, and announced preliminary unaudited fourth quarter and full year 2023 revenue.
- Present updated data from the Phase 1/2 study of vimseltinib in TGCT in the second half of 2024.
- Initiate a Phase 2 proof-of-concept study of vimseltinib for the treatment of cGVHD in the fourth quarter of 2024.
- Initiate a Phase 1 study for DCC-3084, a potential best-in-class pan-RAF inhibitor, in the first half of 2024.
Research,
Clinical Trials,
Other Health,
Biotechnology,
General Health,
Pharmaceutical,
Health,
Science,
Oncology,
Other Science,
Patient,
Gastrointestinal stromal tumor,
Survival,
Risk,
Neoplasm,
INSIGHT,
Progression-free survival,
Disease,
KIT,
DNA,
Cancer,
Liquid biopsy,
Exon,
Death,
Nature Medicine,
Manuscript,
Overalls,
PFS,
Sunitinib,
AP,
GIST,
Pharmaceutical industry “The results published in Nature Medicine provide compelling evidence that QINLOCK may provide progression-free and overall survival benefit to second-line (2L) GIST patients in whom a liquid biopsy reveals primary KIT exon 11 mutations plus secondary mutations restricted to KIT exons 17 and 18.
Key Points:
- “The results published in Nature Medicine provide compelling evidence that QINLOCK may provide progression-free and overall survival benefit to second-line (2L) GIST patients in whom a liquid biopsy reveals primary KIT exon 11 mutations plus secondary mutations restricted to KIT exons 17 and 18.
- “Our ongoing INSIGHT pivotal Phase 3 study is designed to confirm the exceptional efficacy we observed in this exploratory analysis from INTRIGUE.
- A prespecified exploratory objective in INTRIGUE was to evaluate anti-tumor efficacy of QINLOCK according to baseline KIT primary and secondary mutation status.
- In patients with a detectable KIT exon 11 primary mutation (n=157), 52 patients also had mutations in KIT exon 17/18 only and 41 had mutations in KIT exon 13/14 only.
Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 4:30 PM PT / 7:30 PM ET.
Key Points:
- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 4:30 PM PT / 7:30 PM ET.
- A live webcast of the event will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investors.deciphera.com/events-presentations .
- A replay will be archived on the Company’s website for 30 days following the presentation.
